Zepbound (Tirzepatide) Injection Site Reactions: Alternatives Without This Side Effect

How often does Zepbound cause injection site reactions?

The label pools two placebo-controlled weight-management trials, SURMOUNT-1 and SURMOUNT-2: 958 people on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg, treated for up to 72 weeks [1]. Injection site reactions were reported by 2% of the placebo group and by 6%, 8% and 8% at 5 mg, 10 mg and 15 mg [1]. The label counts them among the adverse reactions that occurred in at least 5% of treated patients, and that one term covers bruising, redness, itching, pain and rash at the site [1].

For comparison, in the same pool, any gastrointestinal adverse reaction occurred in 56% of Zepbound patients at every dose versus 30% on placebo, and nausea alone in 25% to 29% versus 8% [1]. Discontinuation for any adverse reaction was 4.8%, 6.3% and 6.7% at 5, 10 and 15 mg versus 3.4% on placebo [1].

When a site reaction is not just a site reaction

In an analysis of 5,025 tirzepatide-treated adults with type 2 diabetes across seven phase 3 trials, patients who developed anti-tirzepatide antibodies reported more hypersensitivity and injection site reactions, but most of those events were nonserious and nonsevere, and most occurred or resolved regardless of antibody status or antibody level [6]. That population had diabetes and was treated in the SURPASS program rather than the Zepbound weight trials [6].

The label's serious warning covers hypersensitivity, not local irritation. Serious reactions including anaphylaxis and angioedema have been reported after marketing; 0.1% of Zepbound-treated patients in the pooled weight trials had a severe hypersensitivity reaction versus none on placebo; and known serious hypersensitivity to tirzepatide or any excipient is a contraindication [1]. The label says to seek medical attention promptly and discontinue Zepbound if a serious hypersensitivity reaction is suspected [1].

Can a different injectable avoid the reaction?

The Zepbound label states that adverse reaction rates from different trials cannot be directly compared [1]. What exists for switching within the class is a retrospective review of 156 adults switched from one incretin analog to another at a single academic center: 96% tolerated the swap, 7 did not, and of those 7, five had gastrointestinal effects and two had injection site reactions [5].

A swap also changes how much weight loss to expect. In SURMOUNT-5, 751 adults with obesity and no diabetes lost 20.2% of body weight on maximum tolerated tirzepatide versus 13.7% on maximum tolerated semaglutide over 72 weeks [7]. The label also says coadministration with any GLP-1 receptor agonist is not recommended [1].

Options that need no needle

Oral semaglutide. A once-daily tablet. In PIONEER-1, 703 adults with type 2 diabetes took oral semaglutide 3 mg, 7 mg or 14 mg, or placebo, for 26 weeks; the 14 mg dose lowered HbA1c by 1.1 percentage points more than placebo and body weight by 2.3 kg more [2]. Absorption depends on the tablet's SNAC component, which buffers the drug locally and allows semaglutide to cross the stomach lining [8]. No injection means no injection site reaction.

Naltrexone-bupropion. A twice-daily oral combination that is not a GLP-1. In COR-I, 1,742 adults with overweight or obesity took naltrexone 32 mg with bupropion 360 mg, a lower naltrexone dose, or placebo for 56 weeks; mean weight change was -6.1% with the 32 mg combination versus -1.3% on placebo [3].

Orforglipron. An oral non-peptide GLP-1 agonist with phase 2 weight-loss data. In a 36-week phase 2 trial, 272 adults with obesity, or overweight plus a weight-related condition, and without diabetes were randomized to orforglipron or placebo; mean weight change ranged from -9.4% to -14.7% across dose groups versus -2.3% on placebo, and 46% to 75% lost at least 10% versus 9% on placebo [4]. Gastrointestinal adverse events led 10% to 17% of participants to discontinue [4].

These trials did not compare the oral drugs with Zepbound.

If the reaction is mild

The label's injection instructions are specific: inject under the skin of the abdomen, thigh or back of the upper arm, rotate the site with each weekly dose, and have another person give upper-arm injections [1]. The label lists three Zepbound presentations, a vial, a prefilled single-dose pen and a single-patient-use KwikPen, and says patients should be trained on the specific one they receive [1].

In Zepbound's pooled weight trials, injection site reactions occurred in 6% to 8% of treated patients versus 2% on placebo [1]. In a separate analysis of tirzepatide trials in adults with type 2 diabetes, most injection site and hypersensitivity reactions were nonserious and nonsevere [6].